Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Sees Significant Growth in Short Interest

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 149,700 shares, an increase of 6.0% from the November 30th total of 141,200 shares. Approximately 0.5% of the company's shares are sold short. Based on an average trading volume of 16,500 shares, the days-to-cover ratio is currently 9.1 days.

Analysts Set New Price Targets

A number of research firms have weighed in on EPRX. RODMAN&RENSHAW raised shares of Eupraxia Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, November 14th. Rodman & Renshaw began coverage on shares of Eupraxia Pharmaceuticals in a research report on Thursday, November 14th. They set a "buy" rating and a $9.00 price objective for the company.

Eupraxia Pharmaceuticals Stock Performance

Shares of NASDAQ:EPRX traded up $0.08 during midday trading on Wednesday, reaching $3.17. The company's stock had a trading volume of 437 shares, compared to its average volume of 15,929. Eupraxia Pharmaceuticals has a fifty-two week low of $2.20 and a fifty-two week high of $5.58. The firm has a 50 day moving average price of $3.13 and a two-hundred day moving average price of $2.78. The firm has a market capitalization of $86.48 million and a price-to-earnings ratio of -4.40.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.